Trials / Completed
CompletedNCT04468971
REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia
Phase 1 Double-Blinded, Randomized, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) In The Treatment Of COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Cellenkos, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety and efficacy of CK0802 in treatment of patients with COVID-19 induced moderate-to-severe PNA-ARDS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CK0802 | Cryopreserved, off the shelf, cord blood derived T regulatory cells |
| DRUG | Placebo | Expicient |
Timeline
- Start date
- 2020-09-29
- Primary completion
- 2021-10-22
- Completion
- 2021-10-22
- First posted
- 2020-07-13
- Last updated
- 2022-03-10
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04468971. Inclusion in this directory is not an endorsement.